Donepezil and Memantine Derivatives for Dual-Function and Prodrug Applications in Alzheimer’s Disease
ACS Chemical Neuroscience · 2025
DOI: 10.1021/acschemneuro.5c00493 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Neuroscience, 2025. Verfasst von Karna Terpstra und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Illinois Urbana-Champaign, 600 S. Matthews Avenue, Urbana, Illinois 61801, United States. Hauptthemen laut MEDLINE: Memantine, Alzheimer Disease, Donepezil, Prodrugs. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, National Science Foundation Graduate Research Fellowship Program, National Institute on Aging.
Themen: Demenz
Abstract (Originalsprache)
The treatment of Alzheimer's disease by acetylcholinesterase (AChE) and N-methyl-d-aspartate receptor (NMDAR) inhibitors is limited by the narrow therapeutic window and adverse side effects of the drugs. This study aims to increase the efficacy and limit the side effects of donepezil, an AChE inhibitor, and memantine, an NMDAR inhibitor, through the addition of amyloid-β (Aβ)-targeting fragments to create dual-function compounds. The incorporation of the amyloid-targeting fragments successfully produced compounds with affinity for Aβ fibrils, and that can stain amyloid plaques in the brains of 5xFAD mice. The donepezil-based compounds showed significant changes in AChE inhibition compared to donepezil due to the incorporation of the Aβ-targeting fragment and as confirmed by molecular docking studies. The memantine-derived compound showed good brain uptake in 5xFAD mice but lacked compatibility with NMDAR inhibition based on in vitro assays and molecular docking. Importantly, the memantine-derived compound acts as a prodrug in vivo, releasing memantine within a pharmacologically relevant time frame. Overall, these findings suggest that dual-function compounds may be useful as drug delivery agents that can be metabolized to release an active drug in areas of the brain rich in amyloid plaques and thus could lead to improved treatments for Alzheimer's disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, University of Illinois Urbana-Champaign, 600 S. Matthews Avenue, Urbana, Illinois 61801, United States.
- Beckman Institute for Advanced Science and Technology, Carle Illinois College of Medicine, The Neuroscience Program, Department of Bioengineering, Carle Woese Institute for Genomic Biology, University of Illinois Urbana…
ORCID-Profile: Liviu M Mirica
Förderung
- NIA NIH HHS
- National Science Foundation Graduate Research Fellowship Program
- National Institute on Aging
Zitieren
APA
Terpstra, K., Gutiérrez, C., Gui, K., & Mirica, L. M. (2025). Donepezil and Memantine Derivatives for Dual-Function and Prodrug Applications in Alzheimer’s Disease. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.5c00493
Vancouver
Terpstra K, Gutiérrez C, Gui K, Mirica LM. Donepezil and Memantine Derivatives for Dual-Function and Prodrug Applications in Alzheimer’s Disease. ACS Chemical Neuroscience. 2025. doi:10.1021/acschemneuro.5c00493
BibTeX
@article{Terpstra2025,
author = {Terpstra, Karna and Gutiérrez, Citlali and Gui, Kai and Mirica, Liviu M},
title = {Donepezil and Memantine Derivatives for Dual-Function and Prodrug Applications in Alzheimer’s Disease},
journal = {ACS Chemical Neuroscience},
year = {2025},
doi = {10.1021/acschemneuro.5c00493}
}
EUVIMED